MX2017012829A - Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos. - Google Patents

Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.

Info

Publication number
MX2017012829A
MX2017012829A MX2017012829A MX2017012829A MX2017012829A MX 2017012829 A MX2017012829 A MX 2017012829A MX 2017012829 A MX2017012829 A MX 2017012829A MX 2017012829 A MX2017012829 A MX 2017012829A MX 2017012829 A MX2017012829 A MX 2017012829A
Authority
MX
Mexico
Prior art keywords
humanized
mhc
human
cell
correceptor
Prior art date
Application number
MX2017012829A
Other languages
English (en)
Inventor
J Murphy Andrew
Macdonald Lynn
Gurer Cagan
Kyratsous Christos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56926255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017012829(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2017012829A publication Critical patent/MX2017012829A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente descripción se describen animales no humanos (por ejemplo, roedores, por ejemplo, ratones o ratas) genéticamente modificados para expresar un correceptor de células T humanizado (por ejemplo, CD4 y/o CD8 humanizado (por ejemplo, CD8a y/o CD8ß), un receptor de célula T (TCR) humano o humanizado que comprende un dominio variable codificado mediante al menos un segmento de gen de región variable del TCR humano y/o un complejo mayor de histocompatibilidad que se une al correceptor de célula T humanizado (por ejemplo, MHC II humano o humanizado (por ejemplo, cadenas del MHC II a y/o MHC II ß) y/o MHC I (por ejemplo, MHC Ia) respectivamente, y opcionalmente, microglobulina ß2 humana o humanizada). Se proporcionan, además, los embriones, tejidos, y células que los expresan. Se proporcionan, además, métodos para crear un animal genéticamente modificado que expresa al menos un correceptor de células T humanizado (por ejemplo, CD4 y/o CD8 humanizados), al menos un MHC humanizado que se asocia con el correceptor de células T humanizado (por ejemplo, MHC II y/o MCH I humanizados, respectivamente) y/o el TCR humanizado. Se proporcionan, además, métodos para el uso de los animales genéticamente modificados que montan una respuesta inmunitaria de células T sustancialmente humanizada para desarrollar agentes terapéuticos humanos.
MX2017012829A 2015-04-06 2016-04-06 Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos. MX2017012829A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562143687P 2015-04-06 2015-04-06
US201562158804P 2015-05-08 2015-05-08
US201562186935P 2015-06-30 2015-06-30
PCT/US2016/026260 WO2016164492A2 (en) 2015-04-06 2016-04-06 Humanized t cell mediated immune responses in non-human animals

Publications (1)

Publication Number Publication Date
MX2017012829A true MX2017012829A (es) 2018-02-23

Family

ID=56926255

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012829A MX2017012829A (es) 2015-04-06 2016-04-06 Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
MX2023002653A MX2023002653A (es) 2015-04-06 2017-10-05 Respuestas inmunitarias mediadas por celulas t humanizadas en animales no humanos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023002653A MX2023002653A (es) 2015-04-06 2017-10-05 Respuestas inmunitarias mediadas por celulas t humanizadas en animales no humanos.

Country Status (24)

Country Link
US (2) US11259510B2 (es)
EP (2) EP4248744A3 (es)
JP (6) JP6796597B2 (es)
KR (2) KR20240132525A (es)
CN (2) CN107666828B (es)
AU (3) AU2016246698B2 (es)
CA (2) CA2980771C (es)
DK (1) DK3280257T3 (es)
ES (1) ES2954865T3 (es)
FI (1) FI3280257T3 (es)
HR (1) HRP20231039T1 (es)
HU (1) HUE064168T2 (es)
IL (4) IL297097B2 (es)
LT (1) LT3280257T (es)
MX (2) MX2017012829A (es)
NZ (1) NZ736031A (es)
PL (1) PL3280257T3 (es)
PT (1) PT3280257T (es)
RS (1) RS64540B1 (es)
RU (1) RU2732628C2 (es)
SG (2) SG10201909320UA (es)
SI (1) SI3280257T1 (es)
SM (1) SMT202300408T1 (es)
WO (1) WO2016164492A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56656B1 (sr) 2011-10-28 2018-03-30 Regeneron Pharma Miševi sa genetski modifikovanim glavnim kompleksom gena tkivne podudarnosti
RS56330B1 (sr) 2011-10-28 2017-12-29 Regeneron Pharma Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc)
CN114891797A (zh) 2011-10-28 2022-08-12 瑞泽恩制药公司 T细胞受体基因修饰小鼠
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
KR20240147707A (ko) 2013-02-20 2024-10-08 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
CN110192541B (zh) 2013-02-22 2022-02-18 瑞泽恩制药公司 表达人源化主要组织相容性复合物的小鼠
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
AU2016358101B2 (en) 2015-11-20 2022-12-01 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized Lymphocyte-activation gene 3
JP6980674B2 (ja) 2016-02-29 2021-12-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. ヒト化ｔｍｐｒｓｓ遺伝子を有する齧歯類
SI3462853T1 (sl) 2016-06-03 2023-05-31 Regeneron Pharmaceuticals, Inc. Glodavci, ki izražajo eksogeno terminalno deoksinukleotidiltransferazo
ES2962277T3 (es) 2017-09-29 2024-03-18 Regeneron Pharma Roedores que comprenden un locus Ttr humanizado y métodos de uso
CN111511903B (zh) * 2017-10-19 2024-10-11 塞勒克提斯公司 用于改善的免疫细胞疗法的nk抑制剂基因的靶向基因整合
IL274740B2 (en) 2017-11-30 2024-06-01 Regeneron Pharma Non-human animals comprising a humanized trkb locus
US11747340B2 (en) 2018-03-24 2023-09-05 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying HLA-associated tumor peptides
JP7328243B2 (ja) 2018-03-26 2023-08-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療薬を試験するためのヒト化げっ歯類
HRP20240999T1 (hr) 2018-07-16 2024-10-25 Regeneron Pharmaceuticals, Inc. Glodavački modeli bolesti ditra i njihova upotreba
EA202191107A1 (ru) 2018-10-23 2021-09-17 Ридженерон Фармасьютикалз, Инк. T-клеточные рецепторы ny-eso-1 и способы их применения
WO2020092839A1 (en) * 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2020206139A1 (en) 2019-04-04 2020-10-08 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
JP7717619B2 (ja) * 2019-05-01 2025-08-04 パクト ファーマ インコーポレイテッド Ｃｄ８改変ｔ細胞療法を使用するがんの治療のための組成物及び方法
EP3801011A1 (en) 2019-06-04 2021-04-14 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
AU2020289581B2 (en) 2019-06-07 2024-11-21 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized albumin locus
CN114616467A (zh) * 2019-10-03 2022-06-10 瑞泽恩制药公司 筛选原代人类细胞中的同源t细胞和表位反应性的高通量方法
AU2021211485A1 (en) 2020-01-24 2022-09-15 Regeneron Pharmaceuticals, Inc. Preferentially expressed antigen in melanoma (PRAME) T cell receptors and methods of use thereof
AU2022249328A1 (en) * 2021-03-31 2023-09-21 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
WO2023092119A2 (en) 2021-11-22 2023-05-25 Ludwig Institute For Cancer Research Ltd Methods for predicting responsiveness to a cancer therapy
CN113999873B (zh) * 2021-12-31 2022-05-20 北京市疾病预防控制中心 一种基因修饰的非人动物的构建方法及其应用
CN115074368B (zh) * 2022-06-09 2023-08-08 澳门科技大学 一种耐药型类风湿性关节炎动物模型的构建及其应用
KR20250077529A (ko) 2022-09-22 2025-05-30 리제너론 파아마슈티컬스, 인크. 인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스
CN120322238A (zh) 2022-10-31 2025-07-15 瑞泽恩制药公司 用过继性细胞治疗与靶向的免疫细胞因子的组合来治疗癌症的方法
WO2024112806A1 (en) * 2022-11-21 2024-05-30 Moonwalk Biosciences, Inc. Generation and use of epigenetic maps for drug discovery
CN120882754A (zh) 2023-04-07 2025-10-31 瑞泽恩制药公司 用淋巴毒素β受体激动剂治疗癌症的方法
IL324813A (en) 2023-05-25 2026-01-01 Regeneron Pharma T-cell receptors that bind to peptides displaying HPV16-, MART1-, CMV-, EBV-, or influenza
TW202520975A (zh) * 2023-08-09 2025-06-01 英商劍橋企業有限公司 基因改造之囓齒動物及囓齒動物細胞以及其等用途
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2026006724A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Prame off-target peptides and uses thereof
WO2026006734A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958678A (en) 1986-08-21 1999-09-28 The Trustees Of Columbia University In The City Of New York DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
EP0950707B1 (en) 1989-07-25 2009-02-18 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9100481D0 (en) 1991-01-10 1991-02-20 Inst Nat Sante Rech Med Genetically engineered mice
WO1993005817A1 (en) 1991-09-19 1993-04-01 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
WO1994006908A1 (en) 1992-09-11 1994-03-31 The Regents Of The University Of California Transgenic non-human animals having targeted lymphocyte transduction genes
US5523226A (en) * 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
GB9315303D0 (en) 1993-07-23 1993-09-08 Zeneca Ltd Polypeptide
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US6002066A (en) 1996-01-16 1999-12-14 Ortho Pharmaceutical Corp. H2-M modified transgenic mice
WO1997032603A1 (en) 1996-03-05 1997-09-12 The Scripps Research Institute Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
ATE423789T1 (de) 1997-09-16 2009-03-15 Univ Oregon Health & Science Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t- zellen
US6372955B1 (en) 1998-02-17 2002-04-16 Ortho Mcneil Pharmaceutical, Inc. Methods for Producing B cells and antibodies from H2-O modified transgenic mice
WO2001027291A1 (en) 1999-10-12 2001-04-19 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US7462486B2 (en) 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
US20030124524A1 (en) 2000-06-23 2003-07-03 Kenneth Kornman Screening assays for identifying modulators of the inflammatory or immune response
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002222610A1 (en) 2000-12-13 2002-06-24 Sumitomo Pharmaceuticals Company, Limited Transgenic animal expressing hla-a24 and utilization thereof
AU2002246733B2 (en) * 2000-12-19 2007-09-20 Altor Bioscience Corporation Transgenic animals comprising a humanized immune system
FR2827302B1 (fr) 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
EP1421115B1 (en) * 2001-08-31 2005-03-02 Avidex Limited Soluble t cell receptor
JP4087338B2 (ja) 2001-11-15 2008-05-21 キリンファーマ株式会社 キメラ非ヒト動物
JP4238138B2 (ja) 2001-12-22 2009-03-11 ４−アンチボディ アーゲー 遺伝的に修飾された脊椎動物前駆体リンパ球の生成方法及び異種結合タンパク質の産生を目的としたその使用。
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
DE10244457A1 (de) 2002-09-24 2004-04-01 Johannes-Gutenberg-Universität Mainz Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
AU2003279820A1 (en) 2002-10-30 2004-06-07 The Wistar Institute Of Anatomy And Biology Mouse model for autoimmune disorders
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
WO2005085438A1 (ja) 2004-03-09 2005-09-15 Nagoya Industrial Science Research Institute ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
CA2651174A1 (en) 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
EP1878798A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
SI2066349T1 (sl) * 2006-09-08 2012-08-31 Medimmune Llc Humanizirana anti-cd19 protitelesa in njihova uporaba v zdravljenju tumorjev, transplantacijah in avtoimunih boleznih
WO2008051854A2 (en) 2006-10-20 2008-05-02 Trustees Of Boston University A tunable genetic switch for regulating gene expression
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2009114400A1 (en) 2008-03-07 2009-09-17 Regeneron Pharmaceuticals, Inc. Es cell-derived mice from diploid host embryo injection
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
WO2010107400A1 (en) 2009-03-20 2010-09-23 Agency For Science, Technology And Research Genetically modified animal and method of obtaining the same
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
GB0917090D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
JP2013538555A (ja) 2010-07-15 2013-10-17 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド Ｍｈｃクラスｉｉとグルタミン酸デカルボキシラーゼ（ｇａｄ）自己抗原性ペプチドとの天然型複合体に対するｔ細胞受容体様特異性を有する単離された高親和性実体
US9557323B2 (en) 2010-09-24 2017-01-31 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
US10765093B2 (en) 2010-11-27 2020-09-08 James Zhu Humanized transgenic animal
MY186903A (en) 2011-10-28 2021-08-26 Regeneron Pharma Humanized il-6 and il-6 receptor
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
RS56330B1 (sr) 2011-10-28 2017-12-29 Regeneron Pharma Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc)
CN114891797A (zh) * 2011-10-28 2022-08-12 瑞泽恩制药公司 T细胞受体基因修饰小鼠
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
RS56656B1 (sr) 2011-10-28 2018-03-30 Regeneron Pharma Miševi sa genetski modifikovanim glavnim kompleksom gena tkivne podudarnosti
EP4389764B1 (en) 2012-11-05 2026-03-18 Regeneron Pharmaceuticals, Inc. Genetically modified rodents and methods of use thereof
KR20240147707A (ko) 2013-02-20 2024-10-08 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
CN110192541B (zh) 2013-02-22 2022-02-18 瑞泽恩制药公司 表达人源化主要组织相容性复合物的小鼠
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
CA2902543A1 (en) * 2013-03-11 2014-10-09 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
EP4249507A3 (en) 2013-03-11 2023-12-27 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules

Also Published As

Publication number Publication date
IL297097A (en) 2022-12-01
JP7555515B1 (ja) 2024-09-24
JP2022140609A (ja) 2022-09-26
IL297097B1 (en) 2025-03-01
IL297097B2 (en) 2025-07-01
HUE064168T2 (hu) 2024-02-28
EP4248744A2 (en) 2023-09-27
JP2020115896A (ja) 2020-08-06
PL3280257T3 (pl) 2023-10-23
AU2022221563A1 (en) 2022-10-13
US20220174921A1 (en) 2022-06-09
KR102699643B1 (ko) 2024-08-28
JP7763820B2 (ja) 2025-11-04
CN113349159B (zh) 2022-11-11
RU2732628C2 (ru) 2020-09-21
RS64540B1 (sr) 2023-09-29
US20180139940A1 (en) 2018-05-24
CN107666828A (zh) 2018-02-06
EP4248744A3 (en) 2023-12-27
IL318990A (en) 2025-04-01
IL284809A (en) 2021-08-31
EP3280257B1 (en) 2023-06-07
DK3280257T3 (da) 2023-09-04
CA2980771A1 (en) 2016-10-13
ES2954865T3 (es) 2023-11-27
US11259510B2 (en) 2022-03-01
CA2980771C (en) 2024-02-06
SG11201707691WA (en) 2017-10-30
JP2026009189A (ja) 2026-01-19
AU2016246698A1 (en) 2017-10-26
FI3280257T3 (fi) 2023-09-07
CA3223798A1 (en) 2016-10-13
CN107666828B (zh) 2021-04-09
JP6796597B2 (ja) 2020-12-09
WO2016164492A2 (en) 2016-10-13
KR20170133498A (ko) 2017-12-05
SMT202300408T1 (it) 2024-01-10
IL284809B (en) 2022-11-01
HRP20231039T1 (hr) 2023-12-22
IL254775A0 (en) 2017-12-31
LT3280257T (lt) 2023-09-25
JP2018513683A (ja) 2018-05-31
PT3280257T (pt) 2023-09-12
IL284809B2 (en) 2023-03-01
RU2017137786A (ru) 2019-05-08
HK1250884A1 (en) 2019-01-18
EP3280257A2 (en) 2018-02-14
SG10201909320UA (en) 2019-11-28
BR112017021250A2 (pt) 2018-06-26
JP2023174872A (ja) 2023-12-08
AU2016246698B2 (en) 2022-06-02
MX2023002653A (es) 2023-03-28
AU2022221563B2 (en) 2025-05-29
JP2024133736A (ja) 2024-10-02
SI3280257T1 (sl) 2023-10-30
NZ736031A (en) 2022-07-29
AU2025203245A1 (en) 2025-05-29
RU2017137786A3 (es) 2019-09-30
CN113349159A (zh) 2021-09-07
KR20240132525A (ko) 2024-09-03
WO2016164492A3 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
MX2017012829A (es) Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
CY1121869T1 (el) Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας
EP4374690A3 (en) Mice expressing humanized t-cell co-receptors
BR112023018874A2 (pt) Camundongos geneticamente modificados compreendendo componentes do sistema imunológico celular humanizado com diversidade melhorada do repertório de tcrb
CY1123714T1 (el) Μη-ανθρωπινα ζωα που εκφραζουν ανθρωποποιημενο cd3 συμπλοκο
CY1123831T1 (el) Γενετικως τροποποιημενοι ποντικοι υποδοχεα τ κυτταρων
MX355726B (es) Ratones transgenicos que expresan moleculas quimericas del complejo mayor de histocompatibilidad (cmh) clase ii.
NZ736031A9 (en) Humanized t cell mediated immune responses in non-human animals
UY36471A (es) Anticuerpos contra el inmunorreceptor (tigit) de linfocitos t con dominios ig y motivos de inhibición del inmunorreceptor basados en tirosina (itim)
MX373286B (es) Roedores humanizados que expresan cadenas pesadas que contienen dominios vl.
EP3724321A4 (en) GENETICALLY MODIFIED IMMORTALIZED CAR-T LYMPHOCYTES TO ELIMINATE T-LYMPHOCYTE RECEPTOR EXPRESSION AND BETA 2-MICROGLOBULIN
MX2024002644A (es) Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales.
MX2022001202A (es) Ratones con genes insertados de sirp¿-il15 humanizadas y métodos para usarlos.
MX2017002459A (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
GB2564823A (en) Compositions and methods for T-cell receptors reprogramming using fusion proteins
CY1119071T1 (el) Εξανθρωποποιημενα il-7 τρωκτικα
PH12018502402A1 (en) Methods of treating autoimmune disease using allogeneic t cells
CL2016002683A1 (es) Proteínas agonistas de los receptores de trail de cadena simple
BR112021018788A2 (pt) Células, tecidos e órgãos personalizados para transplante de um doador (não humano) humanizado, indivi-dualizado, designado livre de patógenos e métodos e produtos relacionados aos mesmos
CY1122072T1 (el) Μη-ανταγωνιστικα αντισωματα κατευθυνομενα εναντι της αλφα αλυσου του εξωκυτταρικου πεδιου υποδοχεα il7 και χρηση αυτων σε θεραπεια καρκινου
CO2019012756A2 (es) Anticuerpos agonistas contra btla y sus usos
MX2018013963A (es) Metodos de inmunoterapia.
MX2025003201A (es) Ratones geneticamente modificados que expresan componentes del sistema inmunitario celular humano
MX2021000586A (es) Ratones transgenicos que expresan moleculas quimericas del complejo mayor de histocompatibilidad (cmh) clase ii.
EP3386436A4 (en) EXTRACELLULAR MATRIX EQUIPMENT OF THE AREOLARY COMPLEX OF A HUMAN MAMILY AND RELATED METHODS